Investor Presentaiton

sanofi Strategic transformation delivered first set of guidance targets 2020-2022 10 consecutive quarters of growth 540bps BOI margin improvement from 2019 to 20221 €2.7bn cost savings re-invested in growth drivers >25 value-creating BD and M&A deals Accelerating digitalization: use of AI and data science at scale BOI margin 30% EPS growth ~16% growth at CER Strong cash flow Ahead of guidance 1. 2018 proforma BOI margin of 24.6% without equity investment in Regeneron sold in May 2020, excluding IFRS16 impacts. 6 Vaccines Investor Event

View entire presentation